Heart failure & cardiomyopathies
Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator
Authors' conclusion
Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD.
Study context
- Population
- Patients with hypertrophic cardiomyopathy implanted with an implantable cardioverter-defibrillator (ICD)
- Participants
- 216 vs 211
- Exposure
- Subcutaneous ICD (S-ICD) vs TV-ICD
- S-ICDn = 216
- TV-ICDn = 211reference
- Outcome
- Appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality
- Follow-up
- 5 years
Methodological detailsconsecutive patients, propensity-adjusted
- Consecutive patients
- Propensity-adjusted
Main finding
As reported in the abstract
S-ICD vs TV-ICDHazard ratio (95% CI)P value
Appropriate ICD interventions
0.32(0.15–0.65)
P = 0.002Inappropriate ICD interventions
0.44(0.20–0.95)
P = 0.038Disease-related complications
0.64(0.27–1.52)
P = 0.309Mortality
0.74(0.29–1.87)
P = 0.521Observational data: associations, not effects.
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Device-related complications · 5 yearsMajor lead-related complications | 0.17 (0.038–0.79) | P = 0.023 | |
| 0.050.21520Hazard ratio (log scale) |
Device-related complications · 5 years
- Similar 5-year rate of device-related complications
Original publication
Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator. Europace. Published 19 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →